FDA knocks back Novartis copy of Amgen's drug Neulasta

(Reuters) - U.S. regulators have declined to approve Novartis' so-called biosimilar copy of Amgen's Neulasta drug that fights infections in cancer patients, the Swiss drugmaker said on Tuesday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news